Immune dysfunction complexity in chronic lymphocytic leukemia ‒ an issue to consider when designing novel therapeutic strategies

References

• Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123(12):1957–1960.
   PubMed Web of Science ®Google Scholar
• Fiorcari S, Maffei R, Audrito V, et al. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016;7(40):65968–65981.
   PubMedGoogle Scholar
• Borge M, Almejun MB, Podaza E, et al. Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica. 2015;100(4):e140–e142.
   PubMed Web of Science ®Google Scholar
• Boissard F, Fournie JJ, Quillet-Mary A, et al. Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients. Blood Cancer J. 2015;5(10):e355–e355.
   PubMedGoogle Scholar
• Boissard F, Laurent C, Ramsay AG, et al. Nurse-like cells impact on disease progression in chronic lymphocytic leukemia. Blood Cancer J. 2016;6(1):e381–e381.
   PubMedGoogle Scholar
• Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309.
   PubMed Web of Science ®Google Scholar
• Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med. 1996;124(3):311–315.
   PubMedGoogle Scholar
• Kramer I, Stilgenbauer S, Dietrich S, et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017;130(12):1477–1480.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–2549.
   PubMed Web of Science ®Google Scholar
• Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117–1127.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Wierda WG, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw. 2015;13(3):326–362.
   PubMed Web of Science ®Google Scholar
• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573–581.
   PubMed Web of Science ®Google Scholar
• Zheng G, Chattopadhyay S, Sud A, et al. Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. Br J Haematol. 2019;185(2):232–239.
   PubMed Web of Science ®Google Scholar
• Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010;116(23):4771–4776.
   PubMed Web of Science ®Google Scholar
• Zent CS, Ding W, Reinalda MS, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma. 2009;50(8):1261–1268.
   PubMed Web of Science ®Google Scholar
• Ringelstein-Harlev S, Avivi I, Fanadka M, et al. Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. Cancer Immunol Immunother. 2018;67(5):739–748.
   PubMed Web of Science ®Google Scholar
• Joss A, Akdis M, Faith A, et al. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol. 2000;30(6):1683–1690.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Weinberg JB, Yoshizaki A, et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013;27(1):170–182.
   PubMed Web of Science ®Google Scholar
• Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180(9):5771–5777.
   PubMed Web of Science ®Google Scholar
• Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. J Clin Invest. 2017;127(3):772–779.
   PubMed Web of Science ®Google Scholar
• Lindner S, Dahlke K, Sontheimer K, et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 2013;73(8):2468–2479.
   PubMed Web of Science ®Google Scholar
• Drennan S, D'Avola A, Gao Y, et al. IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus. Leukemia. 2017;31(8):1686–1694.
   PubMed Web of Science ®Google Scholar
• Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44(3):383–389.
   PubMed Web of Science ®Google Scholar
• Vardi A, Agathangelidis A, Stalika E, et al. Antigen selection shapes the T-cell repertoire in chronic lymphocytic leukemia. Clin Cancer Res. 2016;22(1):167–174.
   PubMed Web of Science ®Google Scholar
• Kowalewski DJ, Schuster H, Backert L, et al. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA. 2015;112(2):E166–175.
   PubMed Web of Science ®Google Scholar
• Rajasagi M, Shukla SA, Fritsch EF, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014;124(3):453–462.
   PubMed Web of Science ®Google Scholar
• Wu J, Xu X, Lee EJ, et al. Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming. Oncotarget. 2016;7(26):40558–40570.
   PubMedGoogle Scholar
• Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612–1621.
   PubMed Web of Science ®Google Scholar
• Gorgun G, Holderried TA, Zahrieh D, et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7):1797–1805.
   PubMed Web of Science ®Google Scholar
• Riches JC, Gribben JG. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. Semin Hematol. 2014;51(3):228–234.
   PubMed Web of Science ®Google Scholar
• Podhorecka M, Dmoszynska A, Rolinski J, et al. T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia–the three-color flow cytometry analysis. Leuk Res. 2002;26(7):657–660.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427–2437.
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4 + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106(6):2018–2025.
   PubMed Web of Science ®Google Scholar
• Piper KP, Karanth M, McLarnon A, et al. Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells. Clin Exp Immunol. 2011;166(2):154–163.
   PubMed Web of Science ®Google Scholar
• Filip AA, Ciseł B, Koczkodaj D, et al. Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages? Blood Cells Mol Dis. 2013;50(4):263–270.,
   PubMed Web of Science ®Google Scholar
• Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113(13):3050–3058.
   PubMed Web of Science ®Google Scholar
• Hanna BS, McClanahan F, Yazdanparast H, et al. Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia. 2016;30(3):570–579.
   PubMed Web of Science ®Google Scholar
• Audrito V, Serra S, Brusa D, et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood. 2015;125(1):111–123.
   PubMed Web of Science ®Google Scholar
• Brusa D, Serra S, Coscia M, et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98(6):953–963.
   PubMed Web of Science ®Google Scholar
• Middleton O, Cosimo E, Dobbin E, et al. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia. 2015;29(1):107–114.
   PubMed Web of Science ®Google Scholar
• Ni Gabhann J, Hams E, Smith S, et al. Btk regulates macrophage polarization in response to lipopolysaccharide. PLoS One. 2014;9(1):e85834.
   PubMed Web of Science ®Google Scholar
• Patel V, Balakrishnan K, Bibikova E, et al. Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23(14):3734–3743.
   PubMed Web of Science ®Google Scholar
• Rajasekaran N, Sadaram M, Hebb J, et al. Three BTK-specific inhibitors, in contrast to ibrutinib, do not antagonize rituximab-dependent NK-cell mediated cytotoxicity. Blood. 2014;124(21):3118–3118.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Ruppert AS, Heerema NA, et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv. 2018;2(14):1705–1718.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Ramsay AG, Zent CS, et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013;121(20):4137–4141.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Zaritskey A, Egyed M, et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2017;4(11):e534–e543.
   PubMed Web of Science ®Google Scholar
• Fink AM, Bahlo J, Robrecht S, et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017;4(10):e475–e486.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111(11):5291–5297.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Hillmen P, Mahadevan D, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(3):417–423.
   PubMed Web of Science ®Google Scholar
• Aue G, Sun C, Liu D, et al. Activation of Th1 immunity within the tumor microenvironment is associated with clinical response to lenalidomide in chronic lymphocytic leukemia. J Immunol. 2018;201(7):1967–1974.
   PubMed Web of Science ®Google Scholar
• Riches JC, Gribben JG. Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia. Curr Cancer Drug Targets. 2016;16(8):689–700.
   PubMed Web of Science ®Google Scholar
• Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301–305.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164(6):811–821.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood. 2008;112(13):5180–5189.
   PubMed Web of Science ®Google Scholar
• Thijssen R, Slinger E, Weller K, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302–306.
   PubMed Web of Science ®Google Scholar
• Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113(18):4403–4413.
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Burger JA, Fu M, et al. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014;16(12):1036–1046.
   PubMed Web of Science ®Google Scholar
• Renault TT, Chipuk JE. Getting away with murder: how does the BCL-2 family of proteins kill with immunity? Ann NY Acad Sci. 2013;1285(1):59–79.
   PubMedGoogle Scholar
• Huergo-Zapico L, Acebes-Huerta A, Gonzalez-Rodriguez AP, et al. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS One. 2014;9(10):e108326.
   PubMed Web of Science ®Google Scholar
• Oflazoglu E, Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs. 2010;2(1):14–19.
   PubMed Web of Science ®Google Scholar
• Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095–2103.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56.
   PubMed Web of Science ®Google Scholar
• Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematol. 2019;6(2):e67–e78.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Siddiqi T, Flinn I, et al. Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). JCO. 2018; 36(15_suppl):7502–7502.
   Web of Science ®Google Scholar
• Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: The CLARITY study. JCO. 2019;37(30):2722–2729.
   PubMed Web of Science ®Google Scholar
• Fiorcari S, Martinelli S, Bulgarelli J, et al. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica. 2015;100(2):253–262.
   PubMed Web of Science ®Google Scholar
• Sagiv-Barfi I, Kohrt HE, Czerwinski DK, et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci USA. 2015;112(9):E966–E972.
   PubMed Web of Science ®Google Scholar
• Geyer MB, Riviere I, Senechal B, et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI Insight. 2019;4(9):e122627.
   Web of Science ®Google Scholar
• Yin Q, Sivina M, Robins H, et al. Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia. J Immunol. 2017;198(4):1740–1747.
   PubMed Web of Science ®Google Scholar
• Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127(8):3052–3064.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. JCO. 2016;34(10):1112–1121.
   PubMed Web of Science ®Google Scholar
• Zolov SN, Rietberg SP, Bonifant CL. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells. Cytotherapy. 2018;20(10):1259–1266.
   PubMed Web of Science ®Google Scholar
• Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–571.
   PubMed Web of Science ®Google Scholar
• Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039–1041.
   PubMed Web of Science ®Google Scholar
• Oppermann S, Ylanko J, Shi Y, et al. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood. 2016;128(7):934–947.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li Y, Yang S, et al. Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma. J Bone Oncol. 2019;17:100245.
   PubMed Web of Science ®Google Scholar
• Stephens DM. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia. Blood. 2019;134(20):1691–1696.
   PubMed Web of Science ®Google Scholar
• Alhakeem SS, Sindhava VJ, McKenna MK, et al. Role of B cell receptor signaling in IL-10 production by normal and malignant B-1 cells. Ann NY Acad Sci. 2015;1362(1):239–249.
   PubMedGoogle Scholar
• Yehudai D, Snir A, Peri R, et al. B cell-activating factor enhances interleukin-6 and interleukin-10 production by ODN-activated human B cells. Scand J Immunol. 2012;76(4):371–377.
   PubMed Web of Science ®Google Scholar